File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors

TitleTargeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors
Authors
Issue Date2016
Citation
Journal of Clinical Investigation, 2016, v. 126, n. 5, p. 1834-1856 How to Cite?
AbstractTargeting multiple components of the MAPK pathway can prolong the survival of patients with BRAFV600E melanoma. This approach is not curative, as some BRAF-mutated melanoma cells are intrinsically resistant to MAPK inhibitors (MAPKi). At the systemic level, our knowledge of how signaling pathways underlie drug resistance needs to be further expanded. Here, we have shown that intrinsically resistant BRAF-mutated melanoma cells with a low basal level of mitochondrial biogenesis depend on this process to survive MAPKi. Intrinsically resistant cells exploited an integrated stress response, exhibited an increase in mitochondrial DNA content, and required oxidative phosphorylation to meet their bioenergetic needs. We determined that intrinsically resistant cells rely on the genes encoding TFAM, which controls mitochondrial genome replication and transcription, and TRAP1, which regulates mitochondrial protein folding. Therefore, we targeted mitochondrial biogenesis with a mitochondrium-targeted, small-molecule HSP90 inhibitor (Gamitrinib), which eradicated intrinsically resistant cells and augmented the efficacy of MAPKi by inducing mitochondrial dysfunction and inhibiting tumor bioenergetics. A subset of tumor biopsies from patients with disease progression despite MAPKi treatment showed increased mitochondrial biogenesis and tumor bioenergetics. A subset of acquired drug-resistant melanoma cell lines was sensitive to Gamitrinib. Our study establishes mitochondrial biogenesis, coupled with aberrant tumor bioenergetics, as a potential therapy escape mechanism and paves the way for a rationale-based combinatorial strategy to improve the efficacy of MAPKi.
Persistent Identifierhttp://hdl.handle.net/10722/318634
ISSN
2023 Impact Factor: 13.3
2023 SCImago Journal Rankings: 4.833
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorZhang, Gao-
dc.contributor.authorFrederick, Dennie T.-
dc.contributor.authorWu, Lawrence-
dc.contributor.authorWei, Zhi-
dc.contributor.authorKrepler, Clemens-
dc.contributor.authorSrinivasan, Satish-
dc.contributor.authorChae, Young Chan-
dc.contributor.authorXu, Xiaowei-
dc.contributor.authorChoi, Harry-
dc.contributor.authorDimwamwa, Elaida-
dc.contributor.authorOpe, Omotayo-
dc.contributor.authorShannan, Batool-
dc.contributor.authorBasu, Devraj-
dc.contributor.authorZhang, Dongmei-
dc.contributor.authorGuha, Manti-
dc.contributor.authorXiao, Min-
dc.contributor.authorRandell, Sergio-
dc.contributor.authorSproesser, Katrin-
dc.contributor.authorXu, Wei-
dc.contributor.authorLiu, Jephrey-
dc.contributor.authorKarakousis, Giorgos C.-
dc.contributor.authorSchuchter, Lynn M.-
dc.contributor.authorGangadhar, Tara C.-
dc.contributor.authorAmaravadi, Ravi K.-
dc.contributor.authorGu, Mengnan-
dc.contributor.authorXu, Caiyue-
dc.contributor.authorGhosh, Abheek-
dc.contributor.authorXu, Weiting-
dc.contributor.authorTian, Tian-
dc.contributor.authorZhang, Jie-
dc.contributor.authorZha, Shijie-
dc.contributor.authorLiu, Qin-
dc.contributor.authorBrafford, Patricia-
dc.contributor.authorWeeraratna, Ashani-
dc.contributor.authorDavies, Michael A.-
dc.contributor.authorWargo, Jennifer A.-
dc.contributor.authorAvadhani, Narayan G.-
dc.contributor.authorLu, Yiling-
dc.contributor.authorMills, Gordon B.-
dc.contributor.authorAltieri, Dario C.-
dc.contributor.authorFlaherty, Keith T.-
dc.contributor.authorHerlyn, Meenhard-
dc.date.accessioned2022-10-11T12:24:12Z-
dc.date.available2022-10-11T12:24:12Z-
dc.date.issued2016-
dc.identifier.citationJournal of Clinical Investigation, 2016, v. 126, n. 5, p. 1834-1856-
dc.identifier.issn0021-9738-
dc.identifier.urihttp://hdl.handle.net/10722/318634-
dc.description.abstractTargeting multiple components of the MAPK pathway can prolong the survival of patients with BRAFV600E melanoma. This approach is not curative, as some BRAF-mutated melanoma cells are intrinsically resistant to MAPK inhibitors (MAPKi). At the systemic level, our knowledge of how signaling pathways underlie drug resistance needs to be further expanded. Here, we have shown that intrinsically resistant BRAF-mutated melanoma cells with a low basal level of mitochondrial biogenesis depend on this process to survive MAPKi. Intrinsically resistant cells exploited an integrated stress response, exhibited an increase in mitochondrial DNA content, and required oxidative phosphorylation to meet their bioenergetic needs. We determined that intrinsically resistant cells rely on the genes encoding TFAM, which controls mitochondrial genome replication and transcription, and TRAP1, which regulates mitochondrial protein folding. Therefore, we targeted mitochondrial biogenesis with a mitochondrium-targeted, small-molecule HSP90 inhibitor (Gamitrinib), which eradicated intrinsically resistant cells and augmented the efficacy of MAPKi by inducing mitochondrial dysfunction and inhibiting tumor bioenergetics. A subset of tumor biopsies from patients with disease progression despite MAPKi treatment showed increased mitochondrial biogenesis and tumor bioenergetics. A subset of acquired drug-resistant melanoma cell lines was sensitive to Gamitrinib. Our study establishes mitochondrial biogenesis, coupled with aberrant tumor bioenergetics, as a potential therapy escape mechanism and paves the way for a rationale-based combinatorial strategy to improve the efficacy of MAPKi.-
dc.languageeng-
dc.relation.ispartofJournal of Clinical Investigation-
dc.titleTargeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1172/JCI82661-
dc.identifier.pmid27043285-
dc.identifier.scopuseid_2-s2.0-84988531155-
dc.identifier.volume126-
dc.identifier.issue5-
dc.identifier.spage1834-
dc.identifier.epage1856-
dc.identifier.eissn1558-8238-
dc.identifier.isiWOS:000375182100021-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats